© Getty Images

AbbVie receives greenlight from NICE for blood cancer treatment

By Isabel Cameron

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (tepkinly), its treatment for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing blood cancer, whose cancer...

Getty Images ©

AbbVie feels biosimilar impact on Humira sales

By Ben Hargreaves

In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.


AbbVie acquires DJS Antibodies

By Rachel Arthur

AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.

(Image: Getty/Utah778)

AbbVie shares fall as Humira lawsuit ramps up

By Maggie Lynch

The California Department of Insurance has sued AbbVie for allegedly providing monetary gifts to health-care providers for prescribing its biologic, Humira.